

Ajay K Gopal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8628467/publications.pdf>

Version: 2024-02-01

191
papers

9,130
citations

61945

43
h-index

43868

91
g-index

192
all docs

192
docs citations

192
times ranked

7926
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
2	PI3K γ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	13.9	956
3	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. <i>Blood</i> , 2008, 112, 2261-2271.	0.6	628
4	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1562-1566.	0.6	324
5	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	3.8	308
6	A phase I/II trial of iodine-131 β -tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	0.6	258
7	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	0.8	216
8	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002, 99, 3158-3162.	0.6	205
9	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1816-1823.	3.2	190
10	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003, 102, 2351-2357.	0.6	187
11	A phase I/II trial of iodine-131 β -tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	0.6	173
12	Allogeneic hematopoietic cell transplantation after conditioning with 131I β -anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 5444-5453.	0.6	161
13	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 560-568.	0.6	157
14	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	0.8	152
15	¹³¹ I β -anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006, 107, 2184-2191.	0.6	146
16	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014, 7, 24.	6.9	144
17	High-Dose [¹³¹ I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults \geq 60 Years Old With Relapsed or Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1396-1402.	0.8	112
18	Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 132, 777-781.	0.6	105

#	ARTICLE	IF	CITATIONS
19	Clinical applications of anti-CD20 antibodies. <i>Translational Research</i> , 1999, 134, 445-450.	2.4	95
20	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213.	2.0	92
21	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
22	Cranial Computed Tomography Before Lumbar Puncture. <i>Archives of Internal Medicine</i> , 1999, 159, 2681.	4.3	83
23	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. <i>Blood</i> , 2008, 112, 830-835.	0.6	81
24	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	0.8	81
25	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	2.5	74
26	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020, 189, 1119-1126.	1.2	69
27	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	0.6	68
28	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	1.7	68
29	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	0.8	68
30	Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 3023-3029.	0.8	66
31	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. <i>Blood</i> , 2010, 116, 4231-4239.	0.6	63
32	90Y-ibrutinomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. <i>Blood</i> , 2011, 118, 1132-1139.	0.6	62
33	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1302-1308.	0.6	62
34	Prospective Analysis of Staphylococcus aureus Bacteremia in Nonneutropenic Adults With Malignancy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1110-1110.	0.8	59
35	Anti-CD45 radioimmunotherapy using ²¹¹ At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. <i>Blood</i> , 2013, 121, 3759-3767.	0.6	59
36	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1363-1368.	2.0	54

#	ARTICLE	IF	CITATIONS
37	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. <i>Blood</i> , 2015, 125, 2111-2119.	0.6	52
38	A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 392-397.	0.2	52
39	Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. <i>Leukemia and Lymphoma</i> , 2010, 51, 1523-1529.	0.6	51
40	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 570-576.	2.0	51
41	A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. <i>Blood</i> , 2009, 113, 4903-4913.	0.6	50
42	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018, 131, 611-620.	0.6	49
43	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	0.6	48
44	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies. <i>Cancer Research</i> , 2014, 74, 1179-1189.	0.4	45
45	Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas. <i>Cancer Research</i> , 2007, 67, 5921-5928.	0.4	43
46	Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1062-1073.	0.6	43
47	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016, 128, 1834-1834.	0.6	42
48	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020, 26, 2524-2534.	3.2	40
49	High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma. <i>Cancer</i> , 2008, 113, 1344-1350.	2.0	38
50	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 380-385.	2.0	37
51	Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 697-702.	2.0	36
52	Radioimmunotherapy-Based Conditioning Regimens for Stem Cell Transplantation. <i>Seminars in Hematology</i> , 2008, 45, 118-125.	1.8	36
53	A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 183-191.	1.2	35
54	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004, 103, 3516-3520.	0.6	33

#	ARTICLE	IF	CITATIONS
55	<sc>R</sc>â€<sc>CHOP</sc> with iodineâ€131 tositumomab consolidation for advanced stage diffuse large <sc>B</sc>â€cell lymphoma (<sc>DLBCL</sc>): <sc>SWOG S</sc>0433. British Journal of Haematology, 2014, 166, 382-389.	1.2	33
56	Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood, 2009, 114, 1226-1235.	0.6	32
57	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOPâ€Rituximab versus CHOP + 131Iodineâ€Tositumomab. Clinical Cancer Research, 2013, 19, 6624-6632.	3.2	32
58	Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood, 2008, 111, 2261-2268.	0.6	31
59	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Research, 2017, 77, 3885-3893.	0.4	31
60	Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1537-1545.	2.0	30
61	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 275-284.	0.2	30
62	The Î±-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood, 2019, 134, 1247-1256.	0.6	30
63	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood, 2016, 127, 352-359.	0.6	29
64	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology, the, 2021, 8, e562-e571.	2.2	28
65	Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models. PLoS ONE, 2015, 10, e0120561.	1.1	27
66	Preserved Activity of CD20-Specific Chimeric Antigen Receptorâ€Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research, 2016, 4, 509-519.	1.6	27
67	The effective use of plerixafor as a realâ€time rescue strategy for patients poorly mobilizing autologous CD34⁺ cells. Journal of Clinical Apheresis, 2012, 27, 81-87.	0.7	26
68	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	3.2	26
69	Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma. Clinical Cancer Research, 2011, 17, 7373-7382.	3.2	25
70	Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1403-1406.	2.0	25
71	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Research, 2016, 76, 6669-6679.	0.4	25
72	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	2.5	25

#	ARTICLE	IF	CITATIONS
73	Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy, 2016, 17, 265-274.	0.9	24
74	High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leukemia and Lymphoma, 2008, 49, 1899-1906.	0.6	23
75	Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia. Cancer Research, 2009, 69, 185-192.	0.4	23
76	131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood, 2009, 113, 5905-5910.	0.6	22
77	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 770-775.	2.0	21
78	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR [®] , therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational New Drugs, 2014, 32, 1213-1225.	1.2	21
79	High-dose (131I)-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. Journal of Nuclear Medicine, 2004, 45, 1059-64.	2.8	21
80	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1582-1587.	2.0	20
81	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. Haematologica, 2020, 105, 1731-1737.	1.7	20
82	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
83	Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. American Journal of Hematology, 2019, 94, E117-E116.	2.0	19
84	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 397-397.	0.6	19
85	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood, 2013, 122, 4382-4382.	0.6	19
86	Myeloablative ¹³¹ I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose. Journal of Nuclear Medicine, 2008, 49, 837-844.	2.8	18
87	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq1 1 0.784314 rgBT /Overl and Leukemia, 2017, 17, 225-230.	0.2	17
88	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. Biology of Blood and Marrow Transplantation, 2018, 24, 1386-1391.	2.0	17
89	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 170-175.	0.2	17
90	The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 1961-1967.	0.6	16

#	ARTICLE	IF	CITATIONS
91	Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6932-6938.	3.2	15
92	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). <i>Blood</i> , 2015, 126, 1543-1543.	0.6	14
93	Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model. <i>PLoS ONE</i> , 2014, 9, e113601.	1.1	13
94	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 4869-4872.	2.5	12
95	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	1.2	11
96	Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16013.	1.8	11
97	Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. <i>Experimental Hematology</i> , 2017, 49, 34-38.e2.	0.2	11
98	Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , 2015, 33, 187-191.	0.8	10
99	Results of a phase I study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 583-590.	1.2	10
100	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw263.	3.0	10
101	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020, 10, 44-52.	1.1	10
102	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018, 132, 94-94.	0.6	10
103	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. <i>Blood</i> , 2006, 108, 316-316.	0.6	10
104	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013, 122, 85-85.	0.6	10
105	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	0.6	10
106	Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 151-157.	0.9	9
107	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
108	Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2012, 47, 8.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2017, 2017, 1-6.	0.3	8
110	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 282-287.	2.0	8
111	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 176-181.	0.2	8
112	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). <i>Blood</i> , 2011, 118, 3711-3711.	0.6	8
113	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	0.6	8
114	Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma Using ¹³¹ I Tositumomab to That of Other Types of Non-Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 738-745.	0.7	7
115	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018, 183, 601-607.	1.2	7
116	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2575-2584.	1.9	7
117	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	2.0	7
118	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	0.6	7
119	Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1789-1789.	0.6	7
120	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
121	Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant. <i>Blood</i> , 2013, 122, 3365-3365.	0.6	7
122	Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 165-174.	0.7	6
123	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I κ B κ kinase downregulation. <i>Anti-Cancer Drugs</i> , 2015, 26, 974-983.	0.7	6
124	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 254-259.	1.4	6
125	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 390-395.	0.2	6
126	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 202-209.	1.3	6

#	ARTICLE	IF	CITATIONS
127	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. <i>Blood</i> , 2011, 118, 3091-3091.	0.6	6
128	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. <i>Leukemia and Lymphoma</i> , 2015, 56, 92-96.	0.6	5
129	Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 661.e1-661.e6.	0.6	5
130	KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 602-609.	0.2	5
131	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma. <i>Blood</i> , 2005, 106, 487-487.	0.6	5
132	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017, 130, 910-910.	0.6	5
133	Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 181-191.	0.7	4
134	90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia. <i>Nuclear Medicine Communications</i> , 2014, 35, 1132-1142.	0.5	4
135	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1300-1306.	2.8	4
136	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3689-3689.	0.6	4
137	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015, 126, 2743-2743.	0.6	4
138	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. <i>Journal of Clinical Oncology</i> , 2018, 36, 7541-7541.	0.8	4
139	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2022, 11, 61-73.	1.3	4
140	Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation. <i>Current Opinion in Oncology</i> , 2010, 22, 143-149.	1.1	3
141	¹³¹ I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 1225-1231.	0.5	3
142	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e87-e90.	0.2	3
143	A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. <i>British Journal of Haematology</i> , 2019, 186, 159-162.	1.2	3
144	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. <i>Blood</i> , 2012, 120, 4164-4164.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 37-45.	2.5	3
146	Radioimmunoconjugates in Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 299-315.	0.2	2
147	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. <i>Clinical Trials</i> , 2016, 13, 545-554.	0.7	2
148	Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. <i>Pharmaceuticals</i> , 2017, 10, 28.	1.7	2
149	Where does transplant fit in the age of targeted therapies?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 287-293.	0.9	2
150	Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact. <i>Lancet Haematology</i> , 2020, 7, e707.	2.2	2
151	Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. <i>British Journal of Haematology</i> , 2020, 190, e332-e335.	1.2	2
152	Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. <i>Blood</i> , 2012, 120, 3687-3687.	0.6	2
153	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 3333-3333.	0.6	2
154	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 4406-4406.	0.6	2
155	Phase 1 Study of TRU-016, An Anti-CD37 SMIP α , β Protein in Relapsed and/or Refractory NHL Patients. <i>Blood</i> , 2011, 118, 1636-1636.	0.6	2
156	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults \geq 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 663-663.	0.6	2
157	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
158	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 48-52.	0.2	1
159	Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 727-741.	0.9	1
160	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells. <i>Blood</i> , 2007, 110, 499-499.	0.6	1
161	Randomized Comparison of Melphalan 200 Mg/m ² v. 280 Mg/m ² As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2009-2009.	0.6	1
162	Bendamustine (Treanda $\text{\textcircled{R}}$), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells. <i>Blood</i> , 2012, 120, 4126-4126.	0.6	1

#	ARTICLE	IF	CITATIONS
163	A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL). Blood, 2013, 122, 4191-4191.	0.6	1
164	What Is the Role of Transplantation for Indolent Lymphoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 494-500.	1.8	1
165	Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma.. Blood, 2005, 106, 2081-2081.	0.6	1
166	Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model. Blood, 2013, 122, 4415-4415.	0.6	1
167	inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.. Journal of Clinical Oncology, 2022, 40, TPS7583-TPS7583.	0.8	1
168	Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPOCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.. Journal of Clinical Oncology, 2022, 40, 7546-7546.	0.8	1
169	Have we found the right patient population for transplantation in follicular lymphoma?. Cancer, 2018, 124, 2484-2487.	2.0	0
170	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Research, 2018, 53, 223.	0.5	0
171	Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL. Journal of Clinical Oncology, 2021, 39, 1671-1673.	0.8	0
172	Radioimmunotherapy of Lymphomas. , 2007, , 147-160.		0
173	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.. Blood, 2007, 110, 1905-1905.	0.6	0
174	A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma. Blood, 2012, 120, 811-811.	0.6	0
175	Anti-CD45 Radioimmunotherapy Using the Alpha-Emitting Radionuclide 211At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model. Blood, 2012, 120, 4096-4096.	0.6	0
176	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 1924-1924.	0.6	0
177	Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model. Blood, 2012, 120, 4101-4101.	0.6	0
178	Phase 1b Study of TRU-016, an Anti-CD37 SMIP α , β Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma. Blood, 2012, 120, 3678-3678.	0.6	0
179	Full Dose Bendamustine (Treanda \AA) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma. Blood, 2012, 120, 3650-3650.	0.6	0
180	131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission. Blood, 2013, 122, 1644-1644.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Bendamustine (Treanda®)-Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation. Blood, 2013, 122, 2033-2033.	0.6	0
182	Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study.. Journal of Clinical Oncology, 2015, 33, 8529-8529.	0.8	0
183	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. Blood, 2015, 126, 1747-1747.	0.6	0
184	Management of transaminase elevations in patients receiving idelalisib.. Journal of Clinical Oncology, 2016, 34, 7532-7532.	0.8	0
185	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. Blood, 2016, 128, 3577-3577.	0.6	0
186	Frequency of Amyloid Subtyping Among Patients with Immunoglobulin Light-Chain Amyloidosis Referred for High-Dose Chemotherapy and Autologous Stem Cell Transplant. Blood, 2016, 128, 5601-5601.	0.6	0
187	Management of Anticoagulation in Patients with Hematologic Malignancy Undergoing Autologous Hematopoietic Cell Transplantation. Blood, 2016, 128, 1437-1437.	0.6	0
188	Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis. Blood, 2018, 132, 198-198.	0.6	0
189	A Phase I trial of talazoparib in patients with advanced hematologic malignancies. International Journal of Hematologic Oncology, 2021, 10, IJH35.	0.7	0
190	A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).. Journal of Clinical Oncology, 2022, 40, TPS7586-TPS7586.	0.8	0
191	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-5.	0.6	0